Shenzhen lixin Thai: A-share issue will not be released so soon

-Our correspondent Shanyu if media news is true, then Shenzhen lixin Thai Pharmaceutical Co., Ltd. (hereinafter referred to as "letter Li Tai") is also expected to get the first batch of IPO pass.　　The IPO will be late, but then the reporter contacted Mr Yang, who said that he had not heard of the news and that the stock issue should not be released so quickly. The first listing application was approved by the Commission last September 16, and the underwriter is the merchant securities.　　In the 33 companies that have already passed the meeting, the company will have a better time.　　As a result, the Thai executives have repeatedly speculated that the company should not have an earlier chance to issue shares. Prior to the issuance of shares, the letter Li Tai Capital structure for Hong Kong Lixin Thai, run compound investment, Li Hong China trade held 95.55%, 3.57%, 0.88% equity.　　After the issuance of the stock, three of the shareholders ' shares were diluted to 71.56%, 2.67% and 0.66% in turn. Letter Li Tai Formerly known as Shenzhen Lixin Thai Pharmaceutical Co., Ltd. was founded in November 1998 for Sino-Foreign joint ventures.　　June 2007, the original letter Li Tai Pharmaceutical industry as a whole changed into a joint-stock company.　　Lixin Thai since its inception, its main business for the raw materials and preparation of the research and development, production and sales, the main varieties of drugs, including cardiovascular, cephalosporins and bone absorption inhibitors such drugs. Plans to raise about 500 million yuan company issued before the total share capital of 85 million shares, the first listed on the scale of 28.5 million shares.　　The funds raised will be invested in 6 projects with a project investment of 520.757 million yuan. According to the relevant consulting company data, 2007, the company's hydrogen sulfate clopidogrel market share of 41.69%, ranked second in the domestic similar products; cefepime hydrochloride injection with the market share of 24.92%, ranked first in domestic similar products, the injection of ceftriaxone sodium market share of 27.15%,　　Ranked second in the domestic similar products. 2006, the market share of benazepril hydrochloride tablets 3.09%, in the industry similar products second.　　The company's main pharmaceutical brands have "Tai Ka", "Letter Power Granville", "Letter Yan", "Letter of Faith", "Letter Kangrui" and so on. At present, the company's products have entered the Beijing Union Hospital, Guangzhou Zhongshan Hospital, the PLA General Hospital, Shanghai Ruijin Hospitals and other more than 5,000 hospitals nationwide.　　At the same time, there are 13 kinds of existing products into the National Health Insurance directory, 2 kinds of access to Guangdong Province Health care directory, for doctors generally recommended medication, patients are more long-term drug groups, the user scale is large and stable.　　The results show that the company's three years before the listing (that is, 2005, 2006, 2007) operating income of 121.614 million yuan, 203.14 million yuan, 349.43 million yuan, the net profit is 8.949 million yuan, 34.238 million yuan, 73.137 million yuan respectively. In the first quarter of 2008, the business income of Lixin Thai was 120.297 million yuan, and the net profit was 25.285 million yuan.